Alternative splicing and cell survival: From tissue homeostasis to disease

Cell Death and Differentiation

Volumn 23, Issue 12, 2016, Pages 1919-1929

  Paronetto, Maria Paola ^a,b,c   Passacantilli, Ilaria ^b,c   Sette, Claudio ^b,c  

^a UNIVERSITY OF ROME FORO ITALICO   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 9; FAS ANTIGEN; PROTEIN BCL XL;

ALTERNATIVE RNA SPLICING; APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL SURVIVAL; DISEASES; GENE CONTROL; HOMEOSTASIS; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE HOMEOSTASIS; TREATMENT RESPONSE; ANIMAL; GENETICS; PATHOLOGY;

ALTERNATIVE SPLICING; ANIMALS; APOPTOSIS; CELL SURVIVAL; DISEASE; HOMEOSTASIS; HUMANS; NEOPLASMS;

EID: 84989244139     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2016.91     Document Type: Review

References (111)

1. Yuan J, Kroemer G. Alternative cell death mechanisms in development and beyond. Genes Dev 2010; 24: 2592-2602.
2. Green DR, Galluzzi L, Kroemer G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 2011; 333: 1109-1112.
3. Green DR, Galluzzi L, Kroemer G. Cell biology. Metabolic control of cell death. Science 2014; 345: 1250256.
4. Green DR. Apoptotic pathways: the roads to ruin. Cell 1998; 94: 695-698.
5. Oppenheim RW. Cell death during development of the nervous system. Annu Rev Neurosci 1991; 14: 453-501.
6. Creedon DJ, Johnson EM Jr, Lawrence JC Jr. Mitogen-activated protein kinaseindependent pathways mediate the effects of nerve growth factor and cAMP on neuronal survival. J Biol Chem 1996; 271: 20713-20718.
7. Purves D, Snider WD, Voyvodic JT. Trophic regulation of nerve cell morphology and innervation in the autonomic nervous system. Nature 1988; 336: 123-128.
8. Matsuda F, Inoue N, Manabe N, Ohkura S. Follicular growth and atresia in mammalian ovaries: regulation by survival and death of granulosa cells. J Reprod Dev 2012; 58: 44-50.
9. Schwerk C, Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell 2005; 19: 1-13.
10. Wahl MC, Will CL, Lührmann R. The spliceosome: design principles of a dynamic RNP machine. Cell 2009; 136: 701-718.
11. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003; 72: 291-336.
12. Fu XD, Ares M Jr. Context-dependent control of alternative splicing by RNA-binding proteins. Nat Rev Genet 2014; 15: 689-701.
13. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
14. Walke DW, Morgan JI. A comparison of the expression and properties of Apaf-1 and Apaf-1 L. Brain Res 2000; 886: 73-81.
15. Wang L, Miura M, Bergeron L, Zhu H, Yuan J. Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell 1994; 78: 739-750.
16. Liu G, Nozell S, Xiao H, Chen X. DeltaNp73beta is active in transactivation and growth suppression. Mol Cell Biol 2004; 24: 487-501.
17. Turnquist C, Horikawa I, Foran E, Major EO, Vojtesek B, Lane DP et al. p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration. Cell Death Differ 2016: 1515-1528.
18. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407: 789-795.
19. Bidere N, Su HC, Lenardo MJ. Genetic disorders of programmed cell death in the immune system. Annu Rev Immunol 2006; 24: 321-352.
20. Cascino I, Papoff G, De Maria R, Testi R, Ruberti G. Fas/Apo-1/CD95 receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol 1996; 156: 13-17.
21. Förch P, Puig O, Kedersha N, Martínez C, Granneman S, Séraphin B et al. The apoptosispromoting factor TIA-1 is a regulator of alternative pre-mRNA splicing. Mol Cell 2000; 6: 1089-1098.
22. Paronetto MP, Bernardis I, Volpe E, Bechara E, Sebestyén E, Eyras E et al. Regulation of FAS exon definition and apoptosis by the Ewing sarcoma protein. Cell Rep 2014; 7: 1211-1226.
23. Förch P, Puig O, Martínez C, Séraphin B, Valcárcel J. The splicing regulator TIA-1 interacts with U1-C to promote U1 snRNP recruitment to 5' splice sites. EMBO J 2002; 21: 6882-6892.
24. Knoop LL, Baker SJ. The splicing factor U1C represses EWS/FLI-mediated transactivation. J Biol Chem 2000; 275: 24865-24871.
25. Izquierdo JM, Majós N, Bonnal S, Martínez C, Castelo R, Guigó R et al. Regulation of Fas alternative splicing by antagonistic effects of TIA-1 and PTB on exon definition. Mol Cell 2005; 19: 475-484.
26. Izquierdo JM, Valcárcel J. Fas-activated serine/threonine kinase (FAST K) synergizes with TIA-1/TIAR proteins to regulate Fas alternative splicing. J Biol Chem 2007; 282: 1539-1543.
27. Izquierdo JM. Hu antigen R (HuR) functions as an alternative pre-mRNA splicing regulator of Fas apoptosis-promoting receptor on exon definition. J Biol Chem 2008; 283: 19077-19084.
28. Bonnal S, Martínez C, Förch P, Bachi A, Wilm M, Valcárcel J. RBM5/Luca-15/H37 regulates Fas alternative splice site pairing after exon definition. Mol Cell 2008; 32: 81-95.
29. Sehgal L, Mathur R, Braun FK, Wise JF, Berkova Z, Neelapu S et al. FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma. Leukemia 2014; 28: 2376-2387.
30. Tejedor JR, Papasaikas P, Valcárcel J. Genome-wide identification of Fas/CD95 alternative splicing regulators reveals links with iron homeostasis. Mol Cell 2015; 57: 23-38.
31. Kumar S. ICE-like proteases in apoptosis. Trends Biochem Sci 1995; 20: 198-202.
32. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-1316.
33. Rodriguez J, Lazebnik Y. Caspase-9 and APAF-1 form an active holoenzyme. Genes Dev 1999; 13: 3179-3184.
34. Kuida K, Haydar TF, Kuan C-Y, Gu Y, Taya C, Karasuyama H et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase-9. Cell 94: 325-3371998.
35. Seol DW, Billiar TR. A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis. J Biol Chem 1999; 274: 2072-2076.
36. Shultz JC, Goehe RW, Murudkar CS, Wijesinghe DS, Mayton EK, Massiello A et al. SRSF1 regulates the alternative splicing of caspase-9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells. Mol Cancer Res 2011; 9: 889-900.
37. Goehe RW, Shultz JC, Murudkar C, Usanovic S, Lamour NF, Massey DH et al. hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 premRNA processing. J Clin Invest 2010; 120: 3923-3939.
38. Vu NT, Park MA, Shultz JC, Goehe RW, Hoeferlin LA, Shultz MD et al. hnRNP U enhances caspase-9 splicing and is modulated by AKT-dependent phosphorylation of hnRNP L. J Biol Chem 2013; 288: 8575-8584.
39. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama KI, Nakayama K et al. Massive cell death of immature hematopoietic cells and neurons in bcl-x-deficient mice. Science 1995; 267: 1506-1510.
40. Bielli P, Bordi M, Biasio VD, Sette C. Regulation of BCL-X splicing reveals a role for the polypyrimidine tract binding protein (PTBP1/hnRNP I) in alternative 5′ splice site selection. Nucleic Acids Res 2014; 42: 12070-12081.
41. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994; 369: 321-323.
42. Fang W, Rivard JJ, Mueller DL, Behrens TW. Cloning and molecular characterization of mouse bcl-x in B and T lymphocytes. J Immunol 1994; 153: 4388-4398.
43. Shiraiwa N, Inohara N, Okada S, Yuzaki M, Shoji S, Ohta S. An additional form of rat Bcl-x, Bcl-xbeta, generated by an unspliced RNA, promotes apoptosis in promyeloid cells. J Biol Chem 1996; 271: 13258-13265.
44. Ye Q, Press B, Kissler S, Yang XF, Lu L, Bassing CH et al. T cell costimulation through CD28 depends on induction of the Bcl-xgamma isoform: analysis of Bcl-xgammadeficient mice. J Exp Med 2002; 196: 87-95.
45. Garneau D, Revil T, Fisette JF, Chabot B. Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. J Biol Chem 2005; 280: 22641-22650.
46. Paronetto MP, Achsel T, Massiello A, Chalfant CE, Sette C. The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x. J Cell Biol 2007; 176: 929-939.
47. Pedrotti S, Busà R, Compagnucci C, Sette C. The RNA recognition motif protein RBM11 is a novel tissue-specific splicing regulator. Nucleic Acids Res 2012; 40: 1021-1032.
48. Zhou A, Ou AC, Cho A, Benz EJ Jr, Huang SC. Novel splicing factor RBM25 modulates Bclx Pre-mRNA 5' splice site selection. Mol Cell Biol 2008; 28: 5924-5936.
49. Massiello A, Roesser JR, Chalfant CE. SAP155 Binds to ceramide-responsive RNA ciselement 1 and regulates the alternative 5' splice site selection of Bcl-x pre-mRNA. FASEB J 2006; 20: 1680-1682.
50. Cloutier P, Toutant J, Shkreta L, Goekjian S, Revil T, Chabot B. Antagonistic effects of the SRp30c protein and cryptic 5′ splice sites on the alternative splicing of the apoptotic regulator Bcl-x. J Biol Chem 2008; 283: 21315-21324.
51. Revil T, Pelletier J, Toutant J, Cloutier A, Chabot B. Heterogeneous nuclear ribonucleoprotein K represses the production of pro-apoptotic Bcl-xS splice isoform. J Biol Chem 2009; 284: 21458-21467.
52. Moore MJ, Wang Q, Kennedy CJ, Silver PA. An alternative splicing network links cell-cycle control to apoptosis. Cell 2010; 142: 625-636.
53. Dominguez C, Fisette JF, Chabot B, Allain FH. Structural basis of G-tract recognition and encaging by hnRNP F quasi-RRMs. Nat Struct Mol Biol 2010; 17: 853-861.
54. Chalfant CE, Ogretmen B, Galadari S, Kroesen BJ, Pettus BJ, Hannun YA. FAS activation induces dephosphorylation of SR proteins; dependence on the de novo generation of ceramide and activation of protein phosphatase 1. J Biol Chem 2001; 276: 44848-44855.
55. Chalfant CE, Rathman K, Pinkerman RL, Wood RE, Obeid LM, Ogretmen B et al. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem 2002; 277: 12587-12595.
56. Obeid LM, Linardic CM, Karolak LA, Hannun YA. Programmed cell death induced by ceramide. Science 1993; 259: 1769-1771.
57. Frisone P, Pradella D, Di Matteo A, Belloni E, Ghigna C, Paronetto MP. SAM68: Signal transduction and RNA metabolism in human cancer. Biomed Res Int 2015; 2015: 528954.
58. Bielli P, Busà R, Di Stasi SM, Munoz MJ, Botti F, Kornblihtt AR et al. The transcription factor FBI-1 inhibits SAM68-mediated BCL-X alternative splicing and apoptosis. EMBO Rep 2014; 15: 419-427.
59. Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo SX, Low DH et al. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Invest 2015; 126: 68-84.
60. DeOcesano-Pereira C, Amaral MS, Parreira KS, Ayupe AC, Jacysyn JF, Amarante-Mendes GP et al. Long non-coding RNA INXS is a critical mediator of BCL-XS induced apoptosis. Nucleic Acids Res 2014; 42: 8343-8355.
61. Zhang J, Manley JL. Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov 2013; 3: 1228-1237.
62. Chen J, Weiss WA. Alternative splicing in cancer: implications for biology and therapy. Oncogene 2015; 34: 1-14.
63. Sveen A, Kilpinen S, Ruusulehto A, Lothe RA, Skotheim RI. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene 2015; 35: 2413-2427.
64. Pagliarini V, Naro C, Sette C. Splicing regulation: a molecular device to enhance cancer cell adaptation. Biomed Res Int 20152015: 543067.
65. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9: 749-758.
66. Rosso M, Okoro DE, Bargonetti J. Splice variants of MDM2 in oncogenesis. Subcell Biochem 2014; 85: 247-261.
67. Mercatante DR, Mohler JL, Kole R. Cellular response to an antisense-mediated shift of Bclx pre-mRNA splicing and antineoplastic agents. J Biol Chem 2002; 277: 49374-49382.
68. Naro C, Barbagallo F, Chieffi P, Bourgeois CF, Paronetto MP, Sette C. The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival. Nucleic Acids Res 2014; 42: 3218-3227.
69. Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell 2013; 23: 48-62.
70. Wang Y, Chen D, Qian H, Tsai YS, Shao S, Liu Q et al. The splicing factor RBM4 controls apoptosis, proliferation, and migration to suppress tumor progression. Cancer Cell 2014; 26: 374-389.
71. Bauman JA, Li SD, Yang A, Huang L, Kole R. Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res 2010; 38: 8348-8356.
72. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007; 14: 185-193.
73. Eblen ST. Regulation of chemoresistance via alternative messenger RNA splicing. Biochem Pharmacol 2012; 83: 1063-1072.
74. Shkreta L, Chabot B. The RNA splicing response to DNA damage. Biomolecules 2015; 5: 2935-2977.
75. Shkreta L, Froehlich U, Paquet ER, Toutant J, Elela SA, Chabot B. Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes. Mol Cancer Ther 2008; 7: 1398-1409.
76. Muñoz MJ, Pérez Santangelo MS, Paronetto MP, de la Mata M, Pelisch F, Boireau S et al. DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell 2009; 137: 708-720.
77. Dutertre M, Sanchez G, De Cian MC, Barbier J, Dardenne E, Gratadou L et al. Cotranscriptional exon skipping in the genotoxic stress response. Nat Struct Mol Biol 2010; 17: 1358-1366.
78. Fidaleo M, Svetoni F, Volpe E, Miñana B, Caporossi D, Paronetto MP. Genotoxic stress inhibits Ewing sarcoma cell growth by modulating alternative pre-mRNA processing of the RNA helicase DHX9. Oncotarget 2015; 6: 31740-31757.
79. Adesso L, Calabretta S, Barbagallo F, Capurso G, Pilozzi E, Geremia R et al. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene 2013; 32: 2848-2857.
80. Calabretta S, Bielli P, Passacantilli I, Pilozzi E, Fendrich V, Capurso G et al. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene 2016; 35: 2031-2039.
81. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-233.
82. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010; 463: 364-368.
83. Stark M, Bram EE, Akerman M, Mandel-Gutfreund Y, Assaraf YG. Heterogeneous nuclear ribonucleoprotein H1/H2dependent unsplicing of thymidinephosphorylase results in anticancer drug resistance. J Biol Chem 2011; 286: 3741-3754.
84. Busà R, Paronetto MP, Farini D, Pierantozzi E, Botti F, Angelini DF et al. The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells. Oncogene 2007; 26: 4372-4382.
85. Bielli P, Busà R, Paronetto MP, Sette C. The RNA-binding protein Sam68 is a multifunctional player in human cancer. Endocr Relat Cancer 2011; 18: R91-R102.
86. Matter N, Herrlich P, König H. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 2002; 420: 691-695.
87. Paronetto MP, Cappellari M, Busà R, Pedrotti S, Vitali R, Comstock C et al. Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Res 2010; 70: 229-239.
88. Stockley J, Markert E, Zhou Y, Robson CN, Elliott DJ, Lindberg J et al. The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7. Sci Rep 2015; 5: 13426.
89. Busà R, Geremia R, Sette C. Genotoxic stress causes the accumulation of the splicing regulator Sam68 in nuclear foci of transcriptionally active chromatin. Nucleic Acids Res 2010; 38: 3005-3018.
90. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275: 967-969.
91. Haferkamp B, Zhang H, Lin Y, Yeap X, Bunce A, Sharpe J et al. BaxDelta2 is a novel bax isoform unique to microsatellite unstable tumors. J Biol Chem 2012; 287: 34722-34729.
92. Zhang H, Lin Y, Mañas A, Zhao Y, Denning MF, Ma L et al. BaxΔ2 promotes apoptosis through caspase-8 activation in microsatellite unstable colon cancer. Mol. Cancer Res 2014; 12: 1225-1232.
93. McLornan D, Hay J, McLaughlin K, Holohan C, Burnett AK, Hills RK et al. Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. Br J Haematol 2013; 160: 188-198.
94. Knudsen KE. The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Div 2006; 1: 15.
95. Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, Utama FE et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res 2009; 15: 5338-5349.
96. Augello MA, Berman-Booty LD, Carr R 3rd, Yoshida A, Dean JL, Schiewer MJ et al. Consequence of the tumor-associated conversion to cyclin D1b. EMBO Mol Med 2015; 7: 628-647.
97. Olshavsky NA, Comstock CE, Schiewer MJ, Augello MA, Hyslop T, Sette C et al. Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Res 2010; 70: 3975-3984.
98. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012; 9: 16-32.
99. Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, Parvani JG et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther 2009; 8: 2152-2162.
100. Scott GK, Robles R, Park JW, Montgomery PA, Daniel J, Holmes WE et al. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 1993; 13: 2247-2257.
101. Doherty JK, Bond C, Jardim A, Adelman JP, Clinton GM. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Nat Acad Sci USA 1999; 96: 10869-10874.
102. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011; 147: 728-741.
103. Galluzzi L, Pietrocola F, Levine B, Kroemer G. Metabolic control of autophagy. Cell 2014; 159: 1263-1276.
104. Settembre C, Fraldi A, Medina DL, Ballabio A. Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol 2013; 14: 283-296.
105. Cheng B, Xu A, Qiao M, Wu Q, Wang W, Mei Y et al. BECN1s, a short splice variant of BECN1, functions in mitophagy. Autophagy 2015; 11: 2048-2056.
106. Liu C, Ma H, Wu J, Huang Q, Liu JO, Yu L. Arginine68 is an essential residue for the C-terminal cleavage of human Atg8 family proteins. BMC Cell Biol 2013; 14: 27.
107. Ouyang DY, Xu LH, He XH, Zhang YT, Zeng LH, Cai JY et al. Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5. Autophagy 2013; 9: 20-32.
108. Park SM, Ou J, Chamberlain L, Simone TM, Yang H, Virbasius CM et al. U2AF35(S34F) promotes transformation by directing aberrant ATG7 pre-mRNA 3' end Formation. Mol Cell 2016; 62: 479-490.
109. Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011; 478: 123-126.
110. Rigo F, Hua Y, Krainer AR, Bennett CF. Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol 2012; 199: 21-25.
111. Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med 2015; 372: 1104-1113.